Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NL005 in Acute Myocardial Infarction
NCT07586865Phase 2Not yet recruiting
- Sponsor
- Northland Biotech
- Start
- May 2026
- Primary completion
- Aug 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of thymosin beta-4 in ST-segment elevation myocardial infarction (STEMI), sponsored by Northland Biotech. Planned start May 2026; status: not yet recruiting.
02
Drugs
thymosin beta-4
03
Conditions
ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT07586865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07586865.